Skinny Labels and Inducing Infringement after GSK v. Teva (RECORDING)

This month, in GlaxoSmithKline v. Teva Pharmaceuticals, the Federal Circuit reinstated a jury's verdict that Teva infringed GSK's patented method of using a blood pressure drug, even though Teva's product was initially launched with a “skinny label” that didn’t mention the infringing method. The precedential decision has potentially far-reaching impacts in Hatch-Waxman and biosimilar litigation – for research agendas and patent prosecution as well.

Until now, experts say, it’s been settled jurisprudence under Hatch-Waxman that marketing a generic drug (where the composition patent has expired) with a label that carves out a patented use does not give rise to inducement liability. The majority opinion in the split decision, written by Judge Newman, focuses instead on other written materials, such as press releases and product catalogues. At its most far-reaching, the decision could suggest that using the standard FDA rating of “biologically equivalent” to market a generic could be legally dangerous if the product still has one use covered by a patent. Chief Judge Prost wrote a substantive and lengthy dissent.

Panelists include two Hatch-Waxman litigators, one who represents innovator companies and one generic manufacturers, as well as a pharma patent prosecutor. They will discuss:

 

  • The procedural posture of the case from the district court onwards that helped lead to the majority opinion
  • The litigation outlook and strategies for both innovators and generic/biosimilar makers
  • A potential increase in value for method-of-use patents, spurring incremental research and patent filings on new disease indications.
  • Scenarios for appeal and what to do in the meantime.

Jeffrey Hovden

Robins Kaplan LLP

is a partner at Robins Kaplan. He practices patent litigation, with a focus on generic pharmaceutical patent cases under the Hatch-Waxman Act and within the biotechnology industry.

Stephanie Lodise

BakerHostetler

is a partner at BakerHostetler, and co-leader of the firm’s Biotechnology, Chemical, and Pharmaceutical patent prosecution team. She holds a Ph.D. in synthetic organic chemistry and earlier worked as a researcher at a major pharmaceutical company.

Bruce Wexler

Paul Hastings LLP

is the global co-chair of the Intellectual Property practice at Paul Hastings. Bruce is a trial lawyer who represents clients as lead counsel defending patents covering multi-million and multi-billion dollar drug products.

Key:

Complete
Failed
Available
Locked
Skinny Labels and Inducing Infringement after GSK v. Teva (RECORDING)
Open to view video.
Open to view video.
Evaluation Survey
12 Questions
CLE Credit
4 Questions
4 Questions CLE credit will be available for registered attendees only. If you would like CLE credit for this webinar, please complete the following questions. IPO will apply for CLE for all live programs in the majority of the states that require CLE. IPO will not be applying for CLE in the states of Florida, Ohio, South Carolina, West Virginia, or Texas (attorneys in TX may submit up to 5 hours of self-study credit). Once IPO has received approval from the state(s) CLE boards , certificate(s) of attendance will be available for download from your dashboard.
IL Certificate of Attendance
Up to 1.00 CLE credits available  |  Certificate available
Up to 1.00 CLE credits available  |  Certificate available Illinois has approved this course for 1 hour of CLE credit. Only registered attendees that viewed the course are eligible to claim credit. To claim credit, select "Claim Credit" then "View/Print Certificate" for your records.
NJ Certificate of Attendance
Up to 1.20 CLE credits available  |  Certificate available
Up to 1.20 CLE credits available  |  Certificate available New Jersey has approved this webinar for 1.2 hours of CLE credit. Only registered attendees that viewed the program are eligible to claim credit. To claim your credit, select "claim credits" and then "view/print your certificate" for your records.
NY Certificate of Attendance
Up to 1.00 CLE credits available  |  Certificate available
Up to 1.00 CLE credits available  |  Certificate available This course recording was approved in Virginia, a NY approved jurisdiction, for 1 hour of CLE credit. Only registered attendees that viewed the on-demand program are eligible to claim credit. To claim your credit, select “claim credits” and then “view/print your certificate” for your records.
VA Certificate of Attendance
Up to 1.00 CLE credits available  |  Certificate available
Up to 1.00 CLE credits available  |  Certificate available Virginia has approved this webinar for 1 hour of CLE credit. Only registered attendees that viewed the program are eligible to claim credit. To claim your credit, select “claim credits” and then “view/print your certificate” for your records.